Get started
Author

Eli Eyal

Observed names: E Eyal, E. Eyal, Eli Eyal, MSc
OpenAlex ID: A5084035322
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
2011 · Olivier Rascol, Cheryl J Fitzer-Attas, et al. · The Lancet Neurology · 217
A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
2008 · C. Warren Olanow, Robert A. Hauser, et al. · Movement Disorders · 169
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
2018 · Ralf Reilmann, Andrew McGarry, et al. · The Lancet Neurology · 112
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study
2014 · Kara M. Smith, Eli Eyal, et al. · JAMA Neurology · 106
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial
2014 · Werner Poewe, Klaus Seppi, et al. · The Lancet Neurology · 97
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
2007 · Iris Grossman, Nili Avidan, et al. · Pharmacogenetics and Genomics · 74
Immunomodulatory placental‐expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty
2018 · Tobias Winkler, Carsten Perka, et al. · Journal of Cachexia Sarcopenia and Muscle · 66
PDF
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study
2016 · Mario Masellis, Shannon Collinson, et al. · Brain · 63
Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease
2014 · Robert A. Hauser, Dee Silver, et al. · Movement Disorders · 55
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users
2015 · Megan J. Shram, Orit Cohen-Barak, et al. · Journal of Clinical Psychopharmacology · 51
Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence
2016 · Yossi Gilgun-Sherki, Rom E. Eliaz, et al. · Drug and Alcohol Dependence · 43
PDF
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
2014 · Joseph Jankovic, Elijahu Berkovich, et al. · Parkinsonism & Related Disorders · 40
Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology
2024 · Vlad Ratziu, Yusuf Yilmaz, et al. · Hepatology · 32
PDF
A Randomized Controlled Trial of Etilevodopa in Patients With Parkinson Disease Who Have Motor Fluctuations
2006 · Karen Blindauer, Ira Shoulson, et al. · Archives of Neurology · 30
Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies
2016 · Robert A. Hauser, Victor Abler, et al. · International Journal of Neuroscience · 23
Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain
2015 · Martin E. Hale, MD, Thomas R. Zimmerman, MD, et al. · Journal of Opioid Management · 19
Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects
2018 · Anna Elgart, Laura Rabinovich‐Guilatt, et al. · Basic & Clinical Pharmacology & Toxicology · 11
Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005)
2017 · Karl Kieburtz, G. Bernhard Landwehrmeyer, et al. · Neurology · 10
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease
2018 · Ofer Spiegelstein, Dorit Mimrod, et al. · Clinical Pharmacology in Drug Development · 7
PDF
Therapeutic unmet needs in brachioradial pruritus
2025 · Giulia Coscarella, Yael Rosen, et al. · British Journal of Dermatology · 1
Diagnostic unmet needs in brachioradial pruritus
2025 · Giulia Coscarella, Yael Rosen, et al. · Journal of the American Academy of Dermatology
ESDR118 - High unmet medical need in brachioradial pruritus: results from a large patient survey
2022 · Elinor Artsy Navon, Yael Rosen, et al.
Symptomatic efficacy of rasagiline in early PD: A meta-analysis
2015 · Robert A. Hauser, Rom Eliaz, et al. · Parkinsonism & Related Disorders
Efficacy of rasagiline in early Parkinson’s disease (PD): a meta-analysis of data from the tempo and adagio studies
2015 · R.A. Hauser, V. Abler, et al. · Journal of the Neurological Sciences
PDF
(443) Low risk of diversion in a randomized, double-blind, placebo-controlled study of extended-release hydrocodone tablets formulated with abuse-deterrence technology for the treatment chronic low back pain
2015 · M. Hale, T. Zimmerman, et al. · Journal of Pain
PDF
Works count: 27
Citation count: 1,226
H-index: 16
I10-index: 18
Year
Topic
Type